CPC C07K 16/3007 (2013.01) [A61P 35/00 (2018.01); C07K 16/2803 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/41 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] | 10 Claims |
1. A bispecific antibody molecule comprising a first binding part that binds specifically to human CEACAM5 and a second binding part that binds specifically to human CD47 wherein:
a) the first binding part comprises a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein CDRH1 is SEQ ID NO:1, CDRH2 is SEQ ID NO:2 and CDRH3 is SEQ ID NO:3,
b) the first binding part comprises a light chain variable region comprising CDRL1, CDRL2, and CDRL3, wherein CDRL1, CDRL2, and CDRL3 are selected from the group consisting of
b1) SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16, respectively;
b2) SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19, respectively;
b3) SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, respectively;
b4) SEQ ID NO:23, SEQ ID NO:24, and SEQ ID NO:25, respectively; and
b5) SEQ ID NO:26, SEQ ID NO:27, and SEQ ID NO:28, respectively; and
c) the second binding part comprises a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein CDRH1 is SEQ ID NO:1, CDRH2 is SEQ ID NO:2 and CDRH3 is SEQ ID NO:3,
and a light chain variable region comprising CDRL1, CDRL2, and CDRL3, wherein CDRL1 is SEQ ID NO:7, CDRL2 is SEQ ID NO:8, and CDRL3 is SEQ ID NO:9.
|